Neuroleptic malignant syndrome and its controversiesy

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 5, 2010, Pages 429-435

  Margetić, Branimir ^a   Margetić, Branka Aukst ^b  

^a Dr Ivan Barbot Neuropsychiatric Hospital in Popova a   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Catatonia; Differential diagnosis; Neuroleptic malignant syndrome; Serotonin syndrome

Indexed keywords

AMANTADINE; AMOXAPINE; ARIPIPRAZOLE; BACLOFEN; BENZODIAZEPINE; BROMOCRIPTINE; CLOMIPRAMINE; CLOZAPINE; HOMOVANILLIC ACID; LEVODOPA; LITHIUM; METOCLOPRAMIDE; PERPHENAZINE; QUETIAPINE; SEROTONIN; ZIPRASIDONE;

BASAL GANGLION; BRAIN INJURY; CATATONIA; CEREBROSPINAL FLUID; CLINICAL PRACTICE; DELIRIUM TREMENS; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; ELECTROCONVULSIVE THERAPY; GENOTYPE; HUMAN; HYPERACTIVITY; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMISSION; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RABIES; REVIEW; SEROTONIN SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CATATONIA; DIAGNOSIS, DIFFERENTIAL; ELECTROCONVULSIVE THERAPY; HUMANS; INCIDENCE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMITTER AGENTS; PHARMACOEPIDEMIOLOGY; SEROTONIN SYNDROME; SYMPATHETIC NERVOUS SYSTEM;

EID: 77952756658     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1937     Document Type: Review

References (65)

1. Strawn JR, Keck PE, Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870-876. 10.1176/appi.ajp.164.6.870.
2. Isbister GK, Buckley NA. Clomipramine and neuroleptic malignant syndrome: literature on adverse reactions to psychotropic drugs continues to confuse. BMJ 2005; 330: 790-791. 10.1136/bmj.330.7494.790-c.
3. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-1145.
4. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587-1591. 10.1016/S0140- 6736(00)03137-3138
5. American Psychiatric Association. Medication-induced movement disorders: neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Association: Washington D.C., 2000; 795-798.
6. Heyland D, Sauvé M. Neuroleptic malignant syndrome without the use of neuroleptics. CMAJ 1991; 145: 817-819.
7. Ohkoshi N, Satoh D, Nishi M, et al. Neuroleptic malignant-like syndrome due to donepezil and maprotiline. Neurology 2003; 60: 1050-1051. (Pubitemid 36348952)
8. Ananth J, Aduri K, Parameswaran S, et al. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatr 2004; 16: 219-228. 10.1111/j. 0924-2708.2004.00085.x.
9. Friedman LS, Weinrauch LA, D'Elia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med 1987; 147: 1495-1497.
10. Stein MH, Sorscher M, Caroff SN. Neuroleptic malignant syndrome induced by metoclopramide in an infant with Freeman-Sheldon syndrome. Anesth Analg 2006; 103: 786-787. 10.1213/01.ANE.0000227135.46049.B7. (Pubitemid 44542958)
11. Madakasira S. Amoxapine-induced neuroleptic malignant syndrome. DICP 1989; 23: 50-51.
12. Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 145-147. 10.1016/j.pnpbp.2004.10.001.
13. Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1323-1334. 10.1016/0278-5846(95)00269-273
14. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986; 143: 1587-1590. (Pubitemid 17196204)
15. Spivak B, Gonen N, Mester R, et al. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 1996; 11: 207-209. (Pubitemid 26361795)
16. Doongaji DR, Desai AB, Satoskar RS. Metoclopramide in schizophrenia (an open study). J Postgrad Med 1986; 32: 139-145.
17. Adityanjee, Singh S, Singh G, et al. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988; 153: 107-111.
18. Pope HG, Jr, Keck PE, Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143: 1227-1233.
19. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185-202.
20. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28: 530-535. 10.1592/phco.28.4.530.
21. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 2009; 4: 84-93. 10.2174/157488609787354387.
22. Carroll BT, Lee JW. Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry 2004; 65: 1722-1723.
23. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49: 1163-1172.
24. Hall RCW, Appleby B, Hall RCW. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly. South Med J 2005; 98: 114-117. (Pubitemid 40129514)
25. Hall RCW, Hall RCW, Chapman M. Neuroleptic malignant syndrome in the elderly: diagnostic criteria, incidence, risk factors, pathophysiology, and treatment. Clin Geriatr 2006; 14: 39-46. (Pubitemid 43950264)
26. Kohen D, Bristow M. Neuroleptic malignant syndrome. Adv Psychiatr Treat 1996; 2: 151-157.
27. Buckley PF, Hasan S. Atypical neuroleptic malignant syndrome and atypical antipsychotics. Am J Psychiatry 1998; 155: 1626.
28. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156: 169-1180.
29. Kishida I, Kawanishi C, Furuno T, et al. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene. Mol Psychiatry 2004; 9: 293-298. 10.1038/sj.mp. 4001422.
30. Nisijima K, Noguti M, Ishiguro T. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry 1997; 41: 913-914. (Pubitemid 27158390)
31. Jauss M, Krack P, Franz M, et al. Imaging of dopamine receptors with [123I]iodobenzamide singlephoton emission-computed tomography in neuroleptic malignant syndrome. Movement Disord 1996; 11: 726-728. (Pubitemid 26381946)
32. Suzuki A, Kondo T, Otani K, et al. Association of the TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001; 158: 1714-1716. (Pubitemid 32923667)
33. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995; 29: 233-244.
34. Nisijima K, Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990; 27: 280-288.
35. Wieselgren IM, Lindström LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res 1998; 81: 101-110.
36. Scheepers FE, Gispen-deWied CC,Westenberg HG, et al. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 2001; 25: 468-475.
37. Geracioti TD, Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158: 1227-1230.
38. Fujimoto A, Nagao T, Ebara T, et al. Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state. Biol Psychiatry 1983; 18: 1141-1152. (Pubitemid 14228862)
39. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65: 464-470.
40. Suh H, Bronson B, Martin R. Neuroleptic malignant syndrome and lowdose olanzapine. Am J Psychiatry 2003; 160: 796.
41. Bora E, Saffet Gonul A, Akdeniz F, et al. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. Eur Psychiatry 2003; 18: 323. 10.1016/j.eurpsy.2003.07.001.
42. Kang SG, Lee HJ, Lee MS, et al. Atypical neuroleptic malignant syndrome associated with aripiprazole. J Clin Psychopharmacol 2006; 26: 534. 10.1097/01.jcp.0000236661.95200.3e.
43. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389.
44. Feibel JH, Schiffer RB. Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report. Am J Psychiatry 1981; 138: 1115-1116. (Pubitemid 11012821)
45. Baguley IJ. The excitatory:inhibitory ratio model (EIR model):An integrative explanation of acute autonomic overactivity syndromes. Med Hypotheses 2008; 70: 26-35. 10.1016/j.mehy.2007.04.037.
46. Reddy VG. Pharmacotherapy of tetanus - a review. Middle East J Anesthesiol 2002; 16: 419-442.
47. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160: 1233-1241. (Pubitemid 41070938)
48. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. MJA 2007; 187: 361-365.
49. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ 2003; 168: 1439-1442.
50. Hamilton S, Malone K. Serotonin syndrome during treatment with paroxetine and risperidone. J Clin Psychopharmacol 2000; 20: 103-105. (Pubitemid 30056364)
51. Haslett CD, Kumar S. Can olanzapine be implicated in causing serotonin syndrome? Psychiatry Clin Neurosci 2002; 56: 533-535. 10.1046/j.1440-1819.2002. 01050.x.
52. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome: is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry 2003; 2: 10. 10.1186/1475-2832-2-10.
53. Viejo LF, Morales V, Puñal P, et al. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand 2003; 107: 45-49. 10.1034/j. 1600-0447.2003.02385.x.
54. Keck PE, Jr, Pope HG, Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989; 46: 914-918.
55. Lazarus A, Mann SC, Caroff SN. The Neuroleptic Malignant Syndrome and Related Conditions. American Psychiatric Press:Washington, DC, 1989.
56. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 324-328. (Pubitemid 19078193)
57. Mann SC, Caroff SN, Bleier HR, et al. Lethal catatonia. Am J Psychiatry 1986; 143: 1374-1381.
58. White DA. Catatonia and the neuroleptic malignant syndrome-a single entity? Br J Psychiatry 1992; 161: 558-560.
59. Carroll BT, Taylor RE. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 1997; 17: 235-238.
60. Fink M. Catatonia: syndrome or schizophrenia subtype? Recognition and treatment. J Neural Transm 2001; 108: 637-644. 10.1007/s007020170041.
61. Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1182-1183. 10.1016/j.pnpbp.2006.03.029.
62. Blumer D. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings. Compr Psychiatry 1997; 38: 193-201. (Pubitemid 27265803)
63. Northoff G, Demisch L, Wenke J, et al. Plasma homovanillic acid concentrations in catatonia. Biol Psychiatry 1996; 39: 436-443. (Pubitemid 26124563)
64. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 2002; 109: 1453-1467. 10.1007/s00702-002- 0762-z.
65. Kaufman KR, Levitt MJ, Schiltz JF, et al. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry 2006; 18: 201-204. 10.1080/10401230600801259.